FDA clears daily oral medication for specific advanced breast cancer cases
The FDA has granted approval for Etcamah (camizestrant), a daily pill designed to treat specific types of advanced breast cancer involving ESR1 mutations. By using a blood test, doctors can identify treatment resistance ahead of scan results, which enables patients to switch therapies sooner. While clinical trial data indicated improved progression-free survival, further research is required to verify the long-term advantages for patients.
by shortkt.com✓